Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Chat with Yara.AI
Your financial questions, answered anytime, instantly.
Cibil Report
Get cibil report
Do not call
En
Wockhardt Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Low
₹2,025.00
High
₹2,064.00
Price Summary
| Previous Close | ₹2,054.00 |
|---|---|
| Day's Range | ₹2,025.00 - ₹2,064.00 |
| Open | ₹2,034.60 |
| 52 Week Range | ₹1,086.70 - ₹2,422.30 |
| Volume | 3,42,889 |
| Market Cap | ₹0.03 |
| Previous Close | ₹2,056.35 |
|---|---|
| Day's Range | ₹2,029.85 - ₹2,064.00 |
| Open | ₹2,034.70 |
| 52 Week Range | ₹1,086.80 - ₹2,420.00 |
| Volume | 45,530 |
| Market Cap | ₹0.03 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 7,019.17 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 81.51 |
| TTM EPS (₹) | 25.23 |
| P/E Ratio | 89.54 |
| Book Value(₹) | 6.48 |
| PAT Margin (%) | 5.13 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 6.79 |
| Trade Value ( ₹ in Lacs) | 932.64 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 81.51 |
| TTM EPS (₹) | 25.23 |
| P/E Ratio | 89.54 |
| Book Value(₹) | 6.48 |
| PAT Margin (%) | 5.13 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 6.79 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 7820.0 | 14020.0 |
| Expenses | N/A | N/A |
| PBT | 910.0 | -120.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 820.0 | -120.0 |
About Wockhardt Ltd.
| Founded | 1999 |
|---|---|
| Managing Director | Murtaza Khorakiwala |
| NSE Symbol | WOCKPHARMA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,52,706.52 | 1,886.80 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 3,03,961.52 | 11,450.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,79,493.69 | 4,718.95 | 3,672.30 - 3,672.30 |
| Laurus Labs Ltd. | 1,29,410.18 | 2,395.10 | 917.95 - 917.95 |
| Lenskart Solutions Ltd. | 1,26,515.86 | 727.20 | 0.00 - 0.00 |
| Apollo Hospitals Enterprise Ltd. | 1,22,382.31 | 8,511.50 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,20,249.09 | 1,205.50 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,15,768.64 | 1,386.00 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,13,912.22 | 1,410.00 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,08,837.38 | 2,635.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Nov
13
2026
Posted on Nov 13th 2026
Phaarmasia - Quaterly Results
The sales moved down -62.06% to Rs. 62.79 millions for the September 2026 quarter as compared to Rs. 165.51 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2026 is Rs. -0.81 millions as compared to Net Profit of Rs. 17.35 millions of corresponding quarter ended September 2025Operating profit Margin for the quarter ended September 2026 slipped to -1.45% as compared to 17.53% of corresponding quarter ended September 2025
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 62.79 | 165.51 | -62.06 | 145.62 | 234.25 | -37.84 | 472.08 | 243.69 | 93.72 |
| Other Income | 3.52 | 1.40 | 151.43 | 6.53 | 4.55 | 43.52 | 9.61 | 7.46 | 28.82 |
| PBIDT | -1.45 | 17.53 | -108.27 | 2.04 | 21.58 | -90.55 | 28.36 | -12.67 | -323.84 |
| Interest | 0.04 | 0.01 | 300.00 | 0.15 | 0.28 | -46.43 | 2.21 | 0.16 | 1281.25 |
| PBDT | -1.49 | 17.52 | -108.50 | 1.89 | 21.30 | -91.13 | 216.02 | -12.83 | -1783.71 |
| Depreciation | 0.52 | 0.55 | -5.45 | 0.86 | 1.19 | -27.73 | 2.14 | 3.20 | -33.13 |
| PBT | -2.01 | 16.97 | -111.84 | 1.03 | 20.11 | -94.88 | 213.88 | -16.03 | -1434.25 |
| TAX | -1.20 | -0.38 | 215.79 | -1.55 | 0.05 | -3200.00 | 38.15 | -0.13 | -29446.15 |
| Deferred Tax | -1.20 | -0.38 | 215.79 | -1.55 | 0.05 | -3200.00 | 1.05 | -0.13 | -907.69 |
| PAT | -0.81 | 17.35 | -104.67 | 2.58 | 20.06 | -87.14 | 175.73 | -15.90 | -1205.22 |
| Equity | 68.27 | 68.27 | 0.00 | 68.27 | 68.27 | 0.00 | 68.27 | 68.27 | 0.00 |
| PBIDTM(%) | -2.31 | 10.59 | -121.80 | 1.40 | 9.21 | -84.79 | 6.01 | -5.20 | -215.55 |
Read More
Nov
13
2026
Posted on Nov 13th 2026
Albert David - Quaterly Results
The company witnessed a 15.58% growth in the revenue at Rs. 1008.31 millions for the quarter ended September 2026 as compared to Rs. 872.41 millions during the year-ago period.The Total Profit for the quarter ended September 2026 of Rs. 28.80 millions grew from Rs.-33.02 millionsOperating profit for the quarter ended September 2026 rose to 80.13 millions as compared to 3.97 millions of corresponding quarter ended September 2025.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 1008.31 | 872.41 | 15.58 | 2021.67 | 1578.07 | 28.11 | 3335.98 | 3457.68 | -3.52 |
| Other Income | -36.41 | -21.44 | 69.82 | 243.21 | 198.92 | 22.27 | 74.53 | 295.81 | -74.80 |
| PBIDT | 80.13 | 3.97 | 1918.39 | 466.10 | 117.79 | 295.70 | 129.19 | 326.07 | -60.38 |
| Interest | 4.00 | 7.51 | -46.74 | 9.16 | 13.06 | -29.86 | 26.32 | 4.10 | 541.95 |
| PBDT | 76.13 | -3.54 | -2250.56 | 456.94 | 104.73 | 336.30 | 102.87 | 321.97 | -68.05 |
| Depreciation | 25.24 | 22.28 | 13.29 | 48.10 | 46.17 | 4.18 | 97.63 | 69.69 | 40.09 |
| PBT | 50.89 | -25.82 | -297.10 | 408.84 | 58.56 | 598.16 | 5.24 | 252.28 | -97.92 |
| TAX | 22.09 | 7.20 | 206.81 | 60.05 | 12.21 | 391.81 | 20.20 | 80.27 | -74.83 |
| Deferred Tax | -7.15 | 7.20 | -199.31 | 18.83 | 12.21 | 54.22 | -12.75 | 21.03 | -160.63 |
| PAT | 28.80 | -33.02 | -187.22 | 348.79 | 46.35 | 652.51 | -14.96 | 172.01 | -108.70 |
| Equity | 57.07 | 57.07 | 0.00 | 57.07 | 57.07 | 0.00 | 57.07 | 57.07 | 0.00 |
| PBIDTM(%) | 7.95 | 0.46 | 1646.21 | 23.06 | 7.46 | 208.88 | 3.87 | 9.43 | -58.93 |
Read More
Nov
13
2026
Posted on Nov 13th 2026
Alkem Laboratories - Quaterly Results
The revenue for the September 2026 quarter is pegged at Rs. 30713.60 millions, about 20.82% up against Rs. 25420.30 millions recorded during the year-ago period.Net profit stood at Rs. 7624.80 millions compared to Rs. 7236.60 millions in the corresponding previous quarter,high by 5.36%.The company reported a good operating profit of 11134.30 millions compared to 8720.50 millions of corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 30713.60 | 25420.30 | 20.82 | 57390.90 | 49142.00 | 16.79 | 96639.10 | 88134.40 | 9.65 |
| Other Income | 1218.80 | 1013.70 | 20.23 | 2585.00 | 2179.50 | 18.61 | 5551.70 | 5070.60 | 9.49 |
| PBIDT | 11134.30 | 8720.50 | 27.68 | 19865.90 | 16091.10 | 23.46 | 29795.60 | 26632.60 | 11.88 |
| Interest | 147.10 | 127.50 | 15.37 | 322.30 | 255.40 | 26.19 | 572.90 | 761.10 | -24.73 |
| PBDT | 11337.20 | 8593.00 | 31.94 | 19893.60 | 15978.60 | 24.50 | 27791.80 | 25871.50 | 7.42 |
| Depreciation | 585.70 | 585.90 | -0.03 | 1157.90 | 1174.80 | -1.44 | 2565.60 | 2836.10 | -9.54 |
| PBT | 10751.50 | 8007.10 | 34.27 | 18735.70 | 14803.80 | 26.56 | 25226.20 | 23035.40 | 9.51 |
| TAX | 3126.70 | 770.50 | 305.80 | 5411.10 | 1344.60 | 302.43 | 3375.00 | 2138.20 | 57.84 |
| Deferred Tax | -331.50 | -465.10 | -28.73 | -124.50 | -984.40 | -87.35 | -945.00 | -1363.10 | -30.67 |
| PAT | 7624.80 | 7236.60 | 5.36 | 13324.60 | 13459.20 | -1.00 | 21851.20 | 20897.20 | 4.57 |
| Equity | 239.10 | 239.10 | 0.00 | 239.10 | 239.10 | 0.00 | 239.10 | 239.10 | 0.00 |
| PBIDTM(%) | 36.25 | 34.31 | 5.67 | 34.62 | 32.74 | 5.71 | 30.83 | 30.22 | 2.03 |
Read More
Nov
13
2026
Posted on Nov 13th 2026
Vasundhara Rasayans - Quaterly Results
A decrease of about -54.17% in the sales to Rs. 40.43 millions was observed for the quarter ended September 2026. The sales stood at Rs. 88.21 millions during the similar quarter previous year.Net Profit for the quarter ended September 2026 dipped to Rs. 0.39 millions from Rs. 20.58 millions in the corresponding previous quarter.The company reported a degrowth in operating Profit to 1.48 millions from 29.82 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 40.43 | 88.21 | -54.17 | 109.75 | 163.82 | -33.01 | 357.23 | 339.90 | 5.10 |
| Other Income | 3.84 | 8.60 | -55.35 | 7.53 | 15.44 | -51.23 | 29.04 | 23.51 | 23.52 |
| PBIDT | 1.48 | 29.82 | -95.04 | 12.02 | 39.92 | -69.89 | 86.97 | 63.93 | 36.04 |
| Interest | 0.18 | 0.92 | -80.43 | 0.66 | 2.28 | -71.05 | 4.03 | 2.69 | 49.81 |
| PBDT | 1.30 | 28.90 | -95.50 | 11.36 | 37.64 | -69.82 | 82.94 | 61.24 | 35.43 |
| Depreciation | 0.77 | 1.09 | -29.36 | 2.08 | 2.10 | -0.95 | 4.30 | 3.57 | 20.45 |
| PBT | 0.53 | 27.81 | -98.09 | 9.28 | 35.54 | -73.89 | 78.64 | 57.67 | 36.36 |
| TAX | 0.14 | 7.23 | -98.06 | 2.42 | 9.24 | -73.81 | 20.74 | 15.21 | 36.36 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.11 | 0.01 | -1200.00 |
| PAT | 0.39 | 20.58 | -98.10 | 6.86 | 26.30 | -73.92 | 57.90 | 42.46 | 36.36 |
| Equity | 31.78 | 31.78 | 0.00 | 31.78 | 31.78 | 0.00 | 31.78 | 31.78 | 0.00 |
| PBIDTM(%) | 3.66 | 33.81 | -89.17 | 10.95 | 24.37 | -55.06 | 24.35 | 18.81 | 29.44 |
Read More
Nov
13
2026
Posted on Nov 13th 2026
Kwality Pharma - Quaterly Results
The turnover for the September 2026 quarter moved up 62.76% to Rs. 1811.68 millions as compared to Rs. 1113.13 millions during the year-ago period.The Net Profit of the company reported a remarkable increase of 105.63% to Rs. 290.25 millions from Rs. 141.15 millions in previous same quarter.Operating profit for the quarter ended September 2026 rose to 505.69 millions as compared to 262.48 millions of corresponding quarter ended September 2025.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 1811.68 | 1113.13 | 62.76 | 3435.20 | 2227.92 | 54.19 | 5030.59 | 3701.97 | 35.89 |
| Other Income | 7.71 | 8.97 | -14.05 | 13.94 | 12.73 | 9.51 | 28.59 | 19.20 | 48.91 |
| PBIDT | 505.69 | 262.48 | 92.66 | 922.13 | 508.09 | 81.49 | 1210.88 | 823.64 | 47.02 |
| Interest | 29.95 | 28.42 | 5.38 | 56.56 | 56.02 | 0.96 | 109.70 | 98.78 | 11.05 |
| PBDT | 475.74 | 234.06 | 103.26 | 865.57 | 452.07 | 91.47 | 1092.89 | 724.86 | 50.77 |
| Depreciation | 53.58 | 49.56 | 8.11 | 103.50 | 97.16 | 6.53 | 197.94 | 182.58 | 8.41 |
| PBT | 422.16 | 184.50 | 128.81 | 762.07 | 354.91 | 114.72 | 894.95 | 542.28 | 65.03 |
| TAX | 131.91 | 43.35 | 204.29 | 215.56 | 94.43 | 128.27 | 221.46 | 143.38 | 54.46 |
| Deferred Tax | 22.00 | 1.84 | 1095.65 | 19.15 | 9.33 | 105.25 | -8.87 | -15.89 | -44.18 |
| PAT | 290.25 | 141.15 | 105.63 | 546.51 | 260.48 | 109.81 | 673.49 | 398.90 | 68.84 |
| Equity | 103.76 | 103.76 | 0.00 | 103.76 | 103.76 | 0.00 | 103.76 | 103.76 | 0.00 |
| PBIDTM(%) | 27.91 | 23.58 | 18.37 | 26.84 | 22.81 | 17.71 | 24.07 | 22.25 | 8.19 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Wockhardt Ltd. is ₹2,054.00 as of 2026-11-12.
The market capitalisation of Wockhardt Ltd. is ₹33,418.19 as of 2026-11-12.
The 1-year return of Wockhardt Ltd. is 693.80% as of 2026-11-12.
The P/E ratio of Wockhardt Ltd. is 89.54 as of 2026-11-13.
The 52-week high and low of Wockhardt Ltd. are ₹2,422.30 and ₹1,086.70, respectively, as of 2026-11-12.
View More
People Also Ask
Wockhardt Ltd. offers branded generics, biopharmaceuticals and novel antibiotics in areas like cardiology, diabetology, gastroenterology and infectious diseases, with operations across India, the UK and emerging markets.
Wockhardt Ltd. partners through hospital‑focused product portfolios, licensing, contract manufacturing and supplying critical‑care and acute‑care drugs in multiple geographies.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
